

### PRIOR AUTHORIZATION REQUEST FORM

#### EOC ID:

## Zaltrap

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

	Prescriber Name:		
Patient Name:	Supervising Physician:		
		Dhana	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:	Ctate Lie ID:	
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	Λ.	
Primary Phone:	Specialty/facility name (if applicable	<del>2</del> ): 	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information following qu	n for this patient that may support a	approval. Please answer the	
Q1. For what diagnosis is this drug being prescribed (pick	one)?		
☐ Metastatic colorectal cancer (mCRC) ☐ Other			
_	acumentation that use is consisted	at with a patagon, 2A or	
Q2. If you selected "other" in question 1, please provide do higher recommendation per NCCN compendia or guideline		it with a category 2A or	
Q3. Please provide ICD code(s) for diagnosis			
Q4. Please indicate location of administration.			
☐ Home			
☐ Physician office (drug from office stock - buy and bill)			
☐ Physician office (MEMBER to obtain drug from PHARI	MACY with a prescription)		
☐ Other			
Q5. Has the patient resistant to or has progressed followin	g an oxaliplatin-containing regime	en?	
☐ Yes ☐ No			



# PRIOR AUTHORIZATION REQUEST FORM EOC ID:

## Zaltrap

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

blank or illegible may delay the review process.			
	Prescriber Name:	_	
Patient Name:	Supervising Physician:	Supervising Physician:	
Q6. Will the patient be using Zaltrap in combination	ation with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI)?		
☐ Yes ☐ No			
Q7. Is the prescribing physician an Oncologist	or Hematologist?	1	
☐ Yes ☐ No			
Q8. Additional Comments			
Prescriber Signature	Date		
	signing above, I certify that applying the standard review timeframe may llee or the enrollee's ability to regain maximum function		
	medical necessity denial. Requesting providers may speak to the SWHP medical e an opportunity to help impact the decision on a request before coverage has been	ו	
This telecopy transmission contains confidential information belonging	g to the sender that is legally privileged. This information is intended only for the use of the individual or		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document